演題抄録

一般演題(口演)

開催概要
開催回
第51回・2013年・京都
 

Bevacizumab carboplatin paclitaxel for NSCLC with malignant pleural effusion

演題番号 : O46-6

[筆頭演者]
Motohiro Tamiya:1 
[共同演者]
Tomonori Hirashima:1、Akihiro Tamiya:2、Keiko Nakao:2、Kazuhiro Asami:2、Tomomi Yasue:3、Takayuki Shiroyama:1、Naoko Morishita:1、Tadahiro Yamadori:1、Hidekazu Suzuki:1、Norio Okamoto:1、Kyoichi Okishio:4、Tomoya Kawaguchi:2、Shinji Atagi:4、Ichiro Kawase:1

1:Thoracic Malignancy, Osaka Prefectural Medical Center for Respiratory and Allergic Diseases, Japan、2:Thoracic Oncology, Kinki-Chuo Chest Medical Center, Japan、3:Clinical laboratory, Osaka Prefectural Hospital Organization Osaka Prefectural Medical Center for Respiratory and Allergic Diseases, Japan、4:Clinical research center, Kinki-Chuo Chest Medical Center, Japan

 

Background: VEGF is involved in NSCLC with malignant pleural effusion (MPE), but little is known regarding the efficacy of bevacizumab (Bev) with carboplatin-paclitaxel (CP) for NSCLC with MPE.Methods: We prospectively evaluated the efficacy and safety of Bev plus CP in 23 chemotherapy-naive non-squamous NSCLC patients with MPE. Results: The overall response rate was 60.8%; the disease control rate was 87.0%. Sixteen patients received maintenance therapy, following a median of 3 cycles. Median progression-free and overall survival times were 7.1 months (95% CI, 5.6 to 9.4 months) and 11.7 months (95% CI, 7.4 to16.8 months), respectively. Most patients experienced severe hematological toxicities, including Υgrade 3 neutropenia; none experienced severe bleeding events. The MPE control rate improved on combining CP with Bev (CP, 78.3%; CP with Bev, 91.3%; P = 0.08). Conclusion: CP plus Bev was effective and tolerable in chemotherapy-naive non-squamous NSCLC patients with MPE.

キーワード

臓器別:その他

手法別:チーム医療

前へ戻る